Hunter et al16 previously reported that celecoxib significantly reduced lung toxic effects in mice, suggesting the feasibility of using COX-2 inhibitors to treat radiation-induced lung toxic effects as a complement to concurrent radiation therapy of lung cancers. Here, PTGS2 is linked to lung carcinoma.